347187-29-5

Usage

Uses

Used in Organic Synthesis:
2-(Boc-aMino)-2-(3-pyridinyl)acetic Acid is used as a building block in organic synthesis for constructing more complex molecules. Its specific structure and functional groups, including the Boc-protected amino and 3-pyridinyl groups, make it a versatile tool for creating new chemical compounds with tailored properties.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-(Boc-aMino)-2-(3-pyridinyl)acetic Acid is utilized as a key intermediate in the development of novel drugs. Its unique structural features and functional groups allow for the design of molecules with potential therapeutic applications, such as modulating biological pathways or targeting specific receptors.
Used in Drug Design and Development:
2-(Boc-aMino)-2-(3-pyridinyl)acetic Acid is employed as a starting material in drug design and development. Its Boc-protected amino group can be selectively deprotected to enable further chemical modifications, while the 3-pyridinyl group provides opportunities for molecular diversification and optimization of drug candidates.
Used in Medicinal Chemistry:
In medicinal chemistry, 2-(Boc-aMino)-2-(3-pyridinyl)acetic Acid is used as a versatile building block for the synthesis of bioactive molecules. Its structural features and functional groups facilitate the design of compounds with potential therapeutic effects, such as modulating enzyme activity, inhibiting protein-protein interactions, or targeting specific cellular pathways.
Overall, 2-(Boc-aMino)-2-(3-pyridinyl)acetic Acid is a valuable chemical entity with diverse applications in organic synthesis, pharmaceutical research, drug design and development, and medicinal chemistry. Its unique structural and functional properties make it a promising candidate for the creation of new chemical compounds with potential biological activity and therapeutic applications.

Upstream product

• 6419-36-9 3-pyridineacetic acid hydrochloride 
• 138891-55-1 ethyl (±)-2-amino-2-(pyridin-3-yl)acetate 
• 138891-54-0 ethyl 2-(hydroxyimino)-2-(pyridin-3-yl)acetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 110772-44-6 2-amino-2-(pyridin-3-yl)acetic acid 
• 131988-63-1 2-amino-2-(pyridin-3-yl)acetonitrile 
• 500-22-1 3-pyridinecarboxaldehyde 
• 313490-93-6 (RS)-ethyl 2-(t-butoxycarbonylamino)-2-(pyridin-3-yl)acetate 
• 39931-77-6 pyridin-3-yl-acetic acid ethyl ester 

Downstream Products

• 864297-15-4 2-(tert-butoxycarbonyl-amino)-2-(pyridin-3-yl)-acetic acid N-(2-amino-5-chloro-phenyl)-amide 
• 864297-14-3 2-(tert-butoxycarbonyl-amino)-2-(pyridin-3-yl)-acetic acid N'-(2-amino-4-chloro-phenyl)-amide 
• 869785-73-9 2-(N-tert-butoxycarbonyl-amino)-2-pyridin-3-yl-N-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]acetamide 
• 1379796-46-9 (RS)-N-benzyl 2-N-(t-butoxycarbonyl)amino-2-(pyridin-3-yl)acetamide 
• 1379796-22-1 (RS)-N-benzyl 2-amino-2-(pyridin-3-yl)acetamide oxalate 

Relevant academic research and scientific papers

Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: Potent inhibitors of R5 HIV-1 replication

The redesign of the previously reported thiophene-3-yl-methyl urea series, as a result of potential cardiotoxicity, was successfully accomplished, resulting in the identification of a novel potent series of CCR5 antagonists containing the imidazolidinylpiperidinyl scaffold. The main redesign criteria were to reduce the number of rotatable bonds and to maintain an acceptable lipophilicity to mitigate hERG inhibition. The structure-activity relationship (SAR) that was developed was used to identify compounds with the best pharmacological profile to inhibit HIV-1. As a result, five advanced compounds, 6d, 6e, 6i, 6h, and 6k, were further evaluated for receptor selectivity, antiviral activity against CCR5 using (R5) HIV-1 clinical isolates, and in vitro and in vivo safety. On the basis of these results, 6d and 6h were selected for further development.

Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides

N-Benzyl 2-acetamido-2-substituted acetamides, where the 2-substituent is a (hetero)aromatic moiety, are potent anticonvulsants. We report the synthesis and whole animal pharmacological evaluation of 16 analogues where the terminal 2-acetyl group was removed to give the corresponding primary amino acid derivatives (PAADs). Conversion to the PAAD structure led to a substantial drop in seizure protection in animal tests, demonstrating the importance of the N-acetyl moiety for anticonvulsant activity. However, several of the PAADs displayed notable pain-attenuating activities in a mouse model.